August 14, 2017August 14, 2017

Potential Therapy, GLPG1690, Seen to Halt Worsening of Lung Fibrosis in Phase 2 Trial

Topline results from a Phase 2a clinical trial show that GLPG1690 successfully halted the worsening of idiopathic pulmonary fibrosis (IPF) in patients, its developer, the Belgian biotechnology firm Galapagos, announced. A double-blind, randomized, placebo-controlled trial, ... Read more

April 13, 2016April 19, 2016

Phase 2a Clinical Trial for IPF Drug Launched by Galapagos

Idiopathic Pulmonary Fibrosis, News

Galapagos, a clinical-stage biotech that specializes in the discovery and development of small molecule medicines with novel modes of action, recently initiated an exploratory Phase 2a clinical trial (FLORA) with ... Read more